ZVRA Stock Forecast & Price Target

Zevra Therapeutics Inc. has demonstrated strong market traction with its MIPLYFFA launch for Niemann-Pick type C (NPC), achieving $10.1 million in sales in the fourth quarter of 2024, significantly surpassing expectations. The company reported a substantial increase in total prescriptions, from 90 to 109 enrollment forms over a short period, indicating increasing patient demand and a successful outreach strategy within the NPC community. With ongoing efforts to raise awareness among healthcare providers and upcoming expansion plans, Zevra is well-positioned for continued growth in 2025, particularly as it potentially files for European market approval later in the year.

Zevra Therapeutics Inc. reported a significant GAAP net loss of $20.4 million and a fourth-quarter net loss of $35.7 million, raising concerns about its financial viability amidst ongoing operational challenges. The company faces risks stemming from poor payer coverage, recent competitor approvals, and emerging safety issues, all of which could negatively impact sales growth and drug demand. Additionally, Zevra's history of consistent losses and lack of profitability, combined with slow market interest and launch difficulties, further contribute to a pessimistic outlook for its stock performance.